Oral Anticoagulation and Factor VIII Replacement Therapy in Patients With Hemophilia Undergoing Pulsed-Field or Radiofrequency Catheter Ablation for Atrial Fibrillation

Circ Arrhythm Electrophysiol. 2024 Oct;17(10):e012921. doi: 10.1161/CIRCEP.124.012921. Epub 2024 Sep 27.

¹ Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX (S.M., P.G.T., V.M.L.F., C.G., B.M., A.Q.M., J.A., M.B., G.J.G., J.D.B., R.H., A.A.-A., A.N.).
² Department of Electrophysiology, Ospedali Riuniti Hospital, Ancona, Italy (M.C., P.C., A.D.R.).
³ Department of Cardiology, University Hospital (UZ) Brussels, Belgium (D.G.D.R.).
⁴ Department of Electrophysiology, Albert Einstein College of Medicine at Montefiore Hospital, Bronx, NY (L.D.B.).
⁵ Interventional Electrophysiology, Scripps Clinic, San Diego, CA (A.N.).
⁶ Department of Internal Medicine, Metro Health Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH (A.N.).
⁷ Department of Biomedicine and Prevention, Division of Cardiology, University of Tor Vergata, Rome, Italy (A.N.).

No abstract available

Keywords: atrial fibrillation; hemophilia; interquartile range; life expectancy; oral anticoagulation; pulsed-field ablation.

Publication types